

# Alexandra Leary

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3373933/alexandra-leary-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

43  
papers

4,127  
citations

15  
h-index

47  
g-index

47  
ext. papers

5,760  
ext. citations

8.4  
avg, IF

5.18  
L-index

#	Paper	IF	Citations
43	Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 2495-2505	59.2	1061
42	Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , <b>2017</b> , 390, 1949-1961	40	815
41	Endometrial cancer. <i>Lancet, The</i> , <b>2016</b> , 387, 1094-1108	40	797
40	Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 75-87	21.7	706
39	Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, e240-e253	21.7	150
38	The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges. <i>Chinese Journal of Cancer</i> , <b>2015</b> , 34, 4-16		123
37	Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3388-3397	2.2	116
36	Renal toxicities associated with pembrolizumab. <i>CKJ: Clinical Kidney Journal</i> , <b>2019</b> , 12, 81-88	4.5	61
35	Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TRANSPORTEC initiative. <i>Modern Pathology</i> , <b>2018</b> , 31, 1851-1861	9.8	24
34	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). <i>Nature Communications</i> , <b>2021</b> , 12, 2487	17.4	24
33	Surgical Outcomes After Debulking Surgery for Intraabdominal Ovarian Growing Teratoma Syndrome: Analysis of 38 Cases. <i>Annals of Surgical Oncology</i> , <b>2015</b> , 22 Suppl 3, S964-70	3.1	18
32	Results from a Monocentric Long-Term Analysis of 23 Patients with Ovarian Sertoli-Leydig Cell Tumors. <i>Oncologist</i> , <b>2019</b> , 24, 702-709	5.7	18
31	Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors. <i>Gynecologic Oncology</i> , <b>2016</b> , 142, 452-7	4.9	17
30	Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications. <i>International Journal of Cancer</i> , <b>2018</b> , 143, 8-15	7.5	16
29	Staging surgery in early-stage ovarian mucinous tumors according to expansile and infiltrative types. <i>Gynecologic Oncology Reports</i> , <b>2017</b> , 22, 21-25	1.3	15
28	Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 5342-5350	12.9	13
27	Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3494-3505	2.2	13

26	CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 4625-4632	12.9	12
25	Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer. <i>Journal of the National Cancer Institute</i> , <b>2021</b> , 113, 1212-1220	9.7	11
24	Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers. <i>PLoS ONE</i> , <b>2018</b> , 13, e0204973	3.7	11
23	Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer. <i>Gynecologic Oncology</i> , <b>2021</b> , 163, 274-280	4.9	11
22	Should We Cease to Perform Salvage Hysterectomy After Chemoradiation and Brachytherapy in Locally Advanced Cervical Cancer?. <i>Anticancer Research</i> , <b>2019</b> , 39, 2919-2926	2.3	9
21	Results of Fertility-Sparing Surgery for Expansile and Infiltrative Mucinous Ovarian Cancers. <i>Oncologist</i> , <b>2018</b> , 23, 324-327	5.7	9
20	HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes. <i>Cancers</i> , <b>2020</b> , 13,	6.6	9
19	The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma. <i>Gynecologic Oncology</i> , <b>2020</b> , 159, 101-111	4.9	7
18	Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer. <i>Investigational New Drugs</i> , <b>2019</b> , 37, 693-701	4.3	6
17	Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7). <i>JNCI Cancer Spectrum</i> , <b>2020</b> , 4, pkaa026	4.6	5
16	Impact of primary para-aortic lymphadenectomy on distant failure in locally advanced cervical cancer patients treated in the era of image-guided adaptive brachytherapy. <i>Clinical and Experimental Metastasis</i> , <b>2016</b> , 33, 775-785	4.7	5
15	Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study). <i>Gynecologic Oncology</i> , <b>2020</b> , 159, 256-263	4.9	5
14	Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape. <i>Gynecologic Oncology</i> , <b>2021</b> , 160, 279-284	4.9	5
13	Optimizing Local Control in High-Grade Uterine Sarcoma: Adjuvant Vaginal Vault Brachytherapy as Part of a Multimodal Treatment. <i>Oncologist</i> , <b>2017</b> , 22, 182-188	5.7	4
12	Evaluation of a RAD51 functional assay in advanced ovarian cancer, a GINECO/GINEGEPS study.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 5513-5513	2.2	4
11	Immune checkpoint inhibitors in ovarian cancer: where do we stand?. <i>Therapeutic Advances in Medical Oncology</i> , <b>2021</b> , 13, 17588359211039899	5.4	4
10	Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 70, 519-531	7.4	3
9	Tertiary lymphoid structures critical for prognosis in endometrial cancer patients.. <i>Nature Communications</i> , <b>2022</b> , 13, 1373	17.4	3

8	A new score based on biomarker values to predict the prognosis of locally advanced cervical cancer. <i>Gynecologic Oncology</i> , <b>2020</b> , 159, 534-538	4.9	2
7	Predicting tumor response and outcome of second-look surgery with F-FDG PET/CT: insights from the GINECO CHIVA phase II trial of neoadjuvant chemotherapy plus nintedanib in stage IIIc-IV FIGO ovarian cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 1998-2008	8.8	2
6	Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors.. <i>European Journal of Cancer</i> , <b>2022</b> , 166, 87-99	7.5	2
5	Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial. <i>Gynecologic Oncology</i> , <b>2021</b> , 163, 563-568	4.9	1
4	Cervical Cancer and Fertility-Sparing Treatment. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
3	Clinical utility of SMARCA4 testing by immunohistochemistry in rare ovarian tumours. <i>British Journal of Cancer</i> , <b>2020</b> , 122, 564-568	8.7	1
2	Is uterine preservation combined with bilateral salpingo-oophorectomy to promote subsequent fertility safe in infiltrative mucinous ovarian cancer?. <i>Gynecologic Oncology Reports</i> , <b>2017</b> , 22, 52-54	1.3	0
1	Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. <i>International Journal of Gynecological Cancer</i> , <b>2021</b> , 31, 949-958	3.5	0